Beirne Wealth Consulting Services LLC Increases Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Beirne Wealth Consulting Services LLC raised its holdings in Novavax, Inc. (NASDAQ:NVAX) by 65.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,500 shares of the biopharmaceutical company’s stock after buying an additional 6,500 shares during the quarter. Beirne Wealth Consulting Services LLC’s holdings in Novavax were worth $133,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company’s stock worth $97,099,000 after acquiring an additional 1,621,772 shares during the last quarter. Shah Capital Management raised its stake in shares of Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after purchasing an additional 1,333,305 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Novavax by 48.9% during the third quarter. Two Sigma Advisers LP now owns 1,999,400 shares of the biopharmaceutical company’s stock worth $25,252,000 after purchasing an additional 656,900 shares during the period. Bank of Montreal Can lifted its holdings in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after purchasing an additional 517,727 shares during the period. Finally, Geode Capital Management LLC boosted its position in Novavax by 9.5% in the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company’s stock valued at $44,245,000 after buying an additional 304,159 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Novavax has a consensus rating of “Hold” and an average price target of $17.83.

Insider Buying and Selling

In other Novavax news, Director James F. Young sold 4,600 shares of the stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the completion of the sale, the director now owns 14,770 shares of the company’s stock, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,150 shares of company stock valued at $119,641. Corporate insiders own 1.00% of the company’s stock.

Novavax Stock Performance

Novavax stock opened at $8.25 on Wednesday. Novavax, Inc. has a 12 month low of $3.81 and a 12 month high of $23.86. The stock’s 50 day simple moving average is $8.72 and its two-hundred day simple moving average is $10.20.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.